AUTHORS
Fnu Manikanta, PhD, Tomasz W Kaminski, PhD, MSc, PharmD2, Ayyanar Sivanantham, PhD3, Nicholas Swendrowski, MS4, Shane Howe5, Joshua Field, MD6, Prithu Sundd, Ph.D7
AFFILIATIONS
1 Versiti blood research institute, Milwaukee, Wisconsin, United States
2 Versiti blood research institute, Milwaukee, Wisconsin, United States
3 Versiti blood research institute, Milwaukee, Wisconsin, United States
4 Versiti blood research institute, Milwaukee, Wisconsin, United States
5 Versiti Research Blood Insitiute, Milwaukee, Wisconsin, United States
6 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
7 Versiti blood research institute, Milwaukee, Wisconsin, United States
ABSTRACT
Background: Sickle Cell Disease (SCD) is the most common monogenic disorder affecting people of African ancestry. Acute chest syndrome (ACS), a type of acute lung injury, is a major cause of respiratory failure among SCD patients hospitalized with vaso-occlusive pain episodes (VOEs). Lung vaso-occlusion by neutrophil-platelet-erythrocyte aggregates and development of thrombocytopenia contributes to development of ACS. Platelet activation serves as a crucial initiating factor in driving the formation of neutrophil-platelet aggregates, suggesting that therapies designed to attenuate platelet activation may prevent ACS in SCD. However, the signaling pathways responsible for platelet activation that promote lung vaso-occlusion in SCD remain incompletely understood. Circulating DNA, a potent damage associated molecular pattern molecule (DAMP) is abundant in the plasma of SCD patients or mice, and significantly upregulated during ACS. However, whether and how circulating DNA activates platelets, and how it leads to development of ACS in SCD remains unknown. Unlike most blood and vascular cells that express nucleic acid receptor toll-like-receptor-9 (TLR9) in endosomes, platelets express functional TLR9 on their surface enabling direct recognition and binding of circulating DNA. Therefore, we hypothesize that TLR9 dependent uptake of circulating DNA by platelets contributes to its activation leading to platelet-neutrophil aggregation, promotingand development of ACS in SCD.
Aim: To determine whether surface-TLR9 dependent uptake of circulating DNA leads to platelet activation and development of ACS in SCD.
Methods: Townes knock-in humanized control (AS) and SCD (SS) mice were intravenously administered 10 µmol/kg body weight oxy-hemoglobin (IV oxy-Hb) ± TLR9 blocking Ab to induce vaso-occlusive crisis. Intravital (in vivo) multi-photon-excitation fluorescence microscopy of intact lung in live SCD mice was conducted to assess the neutrophil-platelet aggregation, neutrophil extracellular traps (NETs) formation and circulating DNA level in lung microcirculation. Lung histology was performed to assess the development of lung injury. Phospho-proteomic analysis of platelets isolated from SCD or control mice ± IV oxy-Hb was conducted using mass spectrometry and data were analyzed with Perseus. Gene set enrichment analysis was performed to identify enriched pathways and biological processes. Standard flow cytometry and western blot analysis was conducted to assess TLR9 activation in control and SCD mice platelets. Imaging-Flow-Cytometry and DNA quantification study was conducted to assess the presence of DNA in SCD mice platelets. Activation of TLR9 signaling in platelets and presence of circulating DNA levels in the plasma were also assessed in blood samples from SCD patients at steady state and same patients following hospitalization for ACS or VOE.
Results: IV challenge with oxy-Hb led to the occlusion of pulmonary arterioles by neutrophil-platelet aggregates (lung vaso-occlusion), NETs generation in the lungs and development of lung injury in SCD but not control mice. Phospho-proteomic analysis revealed the upregulation of platelet activation pathways in IV oxy-Hb challenged SCD compared to control mice platelets. Circulating DNA was detectable in the lung microcirculation of IV oxy-Hb challenged SCD but not control mice. Flow cytometry and western blots analysis confirmed the presence of TLR9 in both control and SCD mice or patient platelets. Imaging-Flow-Cytometry and DNA quantification studies revealed that increased levels of intracellular DNA in platelets in IV oxy-Hb challenged SCD but not control mice, which was significantly reduced in SCD mice pretreated with anti-TLR9 function blocking Ab Remarkably, intravital lung microscopy revealed that development of lung vaso-occlusion and accumulation of NETs in the lung microcirculation were significantly reduced in IV oxy-Hb challenged SCD mice pretreated with anti-TLR9 function blocking Ab, which was also accompanied by the significant amelioration of lung injury (histology).
Conclusion: Our preliminary findings demonstrate for the first time that uptake of circulating DNA by platelets of SCD mice or patients is TLR9 receptor-dependent, contributes to platelet activation in SCD, and therapeutic blockade of TLR9 prevents development of ACS in SCD mice. Currently, experiments are underway to validate these findings using platelet-specific TLR9 deficient SCD mice.
DISCLOSURES
Fnu Manikanta, PhD: No relevant conflicts of interest to declare.